Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Oxaliplatin and Capecitabine with Radiotherapy in Rectal Cancer
NCT00220051Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2001
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in rectal cancer, sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Pathological Complete Response Rate and Acute Toxicity. Started Nov 2001; status: completed.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00220051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220051.